AI-generated summary
The authors updated a systematic review of randomized controlled trials on rosacea treatments, organized by clinical phenotype, and graded the certainty of evidence. They report that across 152 studies, topical brimonidine had high-certainty evidence for reducing temporarily persistent erythema, and topical azelaic acid and ivermectin had high-certainty evidence for reducing papules and pustules. Evidence for laser and light-based therapies was rated low to moderate certainty.
- Studies included
- 152
- Who or what was studied
- People with rosacea, including those with erythema, telangiectasia, papules/pustules and ocular rosacea
- Limits stated in the abstract
- The abstract does not describe the certainty ratings for all interventions, and several findings rest on low-certainty evidence.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on academic.oup.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Systematic review, GRADE, Laser, Light-emitting diode, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.